Back to Agenda
Session 4 - Models and Biomarkers of Drug-Induced Cardiac Injury
Session Chair(s)
Brian R. Berridge, DVM, PhD
Director, World Wide Animal Research Strategy
GlaxoSmithKline R&D, United States
This session will explore bench to bedside approaches to identifying and monitoring drug-induced cardiac injury. Novel approaches to in vitro modeling will be explored as well as assessing changes in cardiac structure and function in nonclinical studies. Translational approaches to non-invasive detection and monitoring injury and dysfunction will be discussed as will clinical strategies for detecting and managing cardiac liabilities.
Speaker(s)
Cardiotoxicity of Oncology Drugs; High Content Screening of Bioenergetic Modulation of Kinase Inhibitor Mitochondrial Toxicity in hESC Derived Cardiomyocyte
Nick Thomas, PhD
GE Healthcare, United Kingdom
Principal Scientist
Integrated Approaches to in Vivo Nonclinical Modeling of Cardiovascular Liabilities
James Turk, DVM, PhD
Amgen Inc., United States
Pathologist Director
Advances in Translational Biomarkers of Cardiac Injury and Dysfunction
Dana B Walker, DVM, PhD, MS
Novartis Institutes for BioMedical Research, Inc., United States
Director, Translational Safety Biomarkers
Nonclinical Modeling of Patient Susceptibility to Drug-induced Cardiotoxicity
Brian R. Berridge, DVM, PhD
GlaxoSmithKline R&D, United States
Director, World Wide Animal Research Strategy
Have an account?